KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$1.87.

  • Nektar Therapeutics' EPS (Basic) rose 2969.92% to -$1.87 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.63, marking a year-over-year increase of 15314.79%. This contributed to the annual value of -$0.58 for FY2024, which is 6009.91% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' EPS (Basic) is -$1.87, which was up 2969.92% from -$2.95 recorded in Q2 2025.
  • Nektar Therapeutics' EPS (Basic)'s 5-year high stood at $0.04 during Q4 2024, with a 5-year trough of -$3.76 in Q2 2024.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.68 (2021), whereas its average is -$0.94.
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' EPS (Basic) showed a top increase of 11598.84% in 2024 and a maximum decrease of 129259.26% in 2024.
  • Nektar Therapeutics' EPS (Basic) (Quarter) stood at -$0.8 in 2021, then soared by 60.07% to -$0.32 in 2022, then skyrocketed by 31.25% to -$0.22 in 2023, then surged by 115.99% to $0.04 in 2024, then crashed by 5416.37% to -$1.87 in 2025.
  • Its EPS (Basic) stands at -$1.87 for Q3 2025, versus -$2.95 for Q2 2025 and -$0.24 for Q1 2025.